Oragenics rises on purchase of neurological therapies and tech

Oragenics

05/10/2023 15:14

** Shares of drug developer Oragenics  OGEN.A  rise 15.5% to
$3.73
    ** Co says it will acquire Las Vegas-based Odyssey Health's
assets that include drug candidates for concussion and Niemann
Pick Disease Type C, a disease where the body becomes incapable
of transporting cholestrol
    ** Says purchase includes cash payments totaling $1 mln and
8 mln shares of Oragenics' series F convertible preferred stock
    ** Including session moves, shares down ~41.3% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))